IDEAYA Hits Full Enrolment In Pivotal Trial Of Darovasertib For Metastatic Uveal Melanoma

IDEAYA announced completion of targeted full enrollment (435 patients) in the OptimuUM-02 Phase 2/3 trial testing darovasertib plus Pfizer’s crizotinib in first-line HLA*A2-negative metastatic uveal melanoma, a milestone that enables a potential full approval filing; topline progression-free survival data are expected in Q1 2026 to support a possible accelerated U.S. filing. The randomized, multi-arm study compares the combination against investigator’s choice (including checkpoint inhibitors and chemotherapy) with primary endpoints of median PFS and OS; earlier Phase 1/2 data showed median OS of 21.1 months and PFS of 7.0 months. Darovasertib carries FDA Breakthrough Therapy (neoadjuvant), Fast Track (combination) and Orphan Drug designations, underscoring regulatory support for a high-unmet-need indication, and IDYA stock was trading up in pre-market activity.

Analysis

IDEAYA announced completion of targeted full enrollment of 435 patients in the OptimuUM-02 Phase 2/3 trial evaluating darovasertib plus Pfizer’s crizotinib in first-line HLA*A2-negative metastatic uveal melanoma, a milestone the company says enables a potential full approval filing. The randomized, multi-arm, open-label study compares the combination against investigator’s choice (including pembrolizumab, ipilimumab plus nivolumab, or dacarbazine) with primary endpoints of median progression-free survival (PFS) and median overall survival (OS), and IDEAYA expects topline PFS data in Q1 2026 to support a possible accelerated U.S. filing. Earlier Phase 1/2 OptimUM-01 data showed a median OS of 21.1 months and median PFS of 7.0 months in first-line patients (mixed HLA cohorts), and darovasertib has received FDA Breakthrough Therapy (neoadjuvant), Fast Track (combination) and Orphan Drug designations.

The market reaction is modestly positive: IDYA traded in a 12-month range of $13.45 to $37.08 and was indicated pre-market at $35.60, up 5.83%, reflecting investor optimism but also valuation compression toward the year high. Completion of enrollment materially reduces execution risk and preserves the regulatory pathway to accelerated approval if PFS is robust, but the pivotal topline PFS readout in Q1 2026 is binary and will drive near-term valuation changes. The open-label, multi-arm design and the fact that prior Phase 1/2 data included both HLA*A2-negative and HLA*A2-positive cohorts introduce comparability and interpretive risks; OS readouts will lag and may differ from PFS outcomes.

Key Decisions for Investors

• Consider selective exposure to IDYA given enrollment completion and regulatory designations, but size positions modestly because the Q1 2026 topline PFS is a binary catalyst that will drive valuation
• Use option strategies or partial hedges to protect downside ahead of the Q1 2026 readout rather than concentrating in outright long exposure, given trial and open‑label design risks
• Monitor interim safety reports, subgroup data for the HLA*A2-negative cohort, and comparative efficacy versus checkpoint inhibitor arms, since prior Phase 1/2 mixed cohorts limit direct comparability
• Re-evaluate position if shares approach or exceed the 52‑week high (~$37.08) absent new trial-positive data, as pre-market strength may reflect short-term sentiment rather than de‑risked fundamentals